Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Renal Cell Carcinoma

Expert Opinion / Cases · November 04, 2014

Systemic Therapy for Advanced Papillary Cell Carcinoma

Heather Greene MSN, FNP, AOCNP

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Heather Greene MSN, FNP, AOCNP

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Bradley Somer MD

    Bradley G. Somer MD

    Nov 05, 2014

    Interesting case! Some additional questions come to mind - Which genetic syndromes should we test for? Can anything be done to prevent new cancers from forming (and save from local recurrences/dialysis)? What would be the surveillance guidelines? What kind of surgical guidelines if new local tumors form?

  • Angel Rodriguez

    Nov 06, 2014

    In my daily practice clinical, I use sunitinib with good results

  • erich lang

    Nov 28, 2014

    no role for adjuvant therapy

  • Moussa Sissoko

    Dec 16, 2014

    With bilateral papillary RCC one needs to consider hereditary papillary RCC which is an autosomal dominant disease. Would test tumor samples for c-MET (papillary type 1) and Fumarate hydratase (Papillary type 2). As per NCCN guidelines (category 2A) non-clear cell RCC can be treated with Temsirolimus. Clinical trial if available would be highly indicated.

  • Jamil Khatri

    Jan 08, 2015

    Erlotinib _ Bevacizumab.

http://www.ascopost.com/ViewNews.aspx?nid=20589

  • Nov 16, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated